Celsis International - Rule 8 Disclosure
21 May 1998 - 3:20AM
UK Regulatory
RNS No 7959b
CELSIS INTERNATIONAL PLC
20th May 1998
FORM 8.1/8.3
Lodged with Company Announcements Office (which will publicise and
copy to the Panel). Use separate form for each class of
securities in which dealings have been made.
Date of disclosure 20TH MAY 1998
DISCLOSURE UNDER RULES 8.1(a), 8.1(b)(i) AND 8.3 OF THE CITY CODE ON
TAKEOVERS AND MERGERS
Date of dealing 19TH MAY 1998
Dealing in ......... CELSIS INTERNATIONAL ........(name of company)
(1) Class of securities (eg ordinary shares) 5P ORDINARY SHARES
(2) Amount bought Amount sold Price per unit
750,000 - 45.67P
(3) Resultant total of the same class owned or controlled
(and percentage of class) ..........2,755,000 ........ (2.76%)
(4) Party making disclosure ........ AMVESCAP PLC ................
(5) EITHER (a) Name of purchaser/vendor (Note 1) ..............
OR (b) If dealing for discretionary client(s), name of
fund management organisation
................... AMVESCAP PLC ............................
(6) Reason for disclosure (Note 2)
(a) associate of (i) offeror (Note 3) NO
(ii) offeree company NO
Specify which category or categories of
associate (1-8 overleaf) .....................................
If category (8), explain ......................................
...............................................................
(b)Rule 8.3 (ie disclosure because of ownership or control of
1% or more of the class of relevant securities dealt in)YES
Signed, for and on behalf of the party named in (4) above A. TULLY
(Also print name of signatory) ........ANGELA TULLY................
Telephone and extension number 0171-454 3652 .......................
----------------------------------
Note 1 Specify owner, not nominee or vehicle company. If
relevant, also identify controller of owner, eg where an
owner normally acts on instructions of a controller.
Note 2 Disclosure might be made for more than one reason; if so,
state all reasons.
Note 3 Specify which offeror if there is more than one.
Note 4 When an arrangement exists with any offeror, with the
offeree company or with an associate of any offeror or of
the offeree company in relation to relevant securities,
details of such arrangement must be disclosed, as required
by Note 6 on Rule 8.
Note 5 It may be necessary, particularly when disclosing
derivative transactions, to append a sheet to this
disclosure form so that all relevant information can be
given.
Note 6 In the case of an average price bargain, each underlying
trade should be disclosed.
For full details of disclosure requirements, see Rule 8 of the Code.
If in doubt, contact the Panel on Takeovers and Mergers, Tel. No.
0171-382 9026.
END
DCCMLGZKNGZLRMM
Celadon Pharmaceuticals (LSE:CEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Celadon Pharmaceuticals (LSE:CEL)
Historical Stock Chart
From Jul 2023 to Jul 2024